

Han W Tun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6790194/publications.pdf>

Version: 2024-02-01

85
papers

1,363
citations

430874

18
h-index

377865

34
g-index

85
all docs

85
docs citations

85
times ranked

2118
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
2	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
3	Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e485-e494.	0.4	5
4	Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 17-21.	2.7	2
5	Real World Long-term Follow-up Experience with Yttrium-90Âibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 618-625.	0.4	4
6	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
7	Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 23-29.	2.7	3
8	A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. <i>Blood Advances</i> , 2022, 6, 4241-4250.	5.2	5
9	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19532-e19532.	1.6	0
10	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7575-7575.	1.6	3
11	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.9	5
12	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
13	BRAF p.V600E associated poly-neoplastic syndrome. <i>Rare Tumors</i> , 2021, 13, 203636132110129.	0.6	4
14	Impact of hypoalbuminemia on the prognosis of relapsed/refractory Bâ€cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
15	Primary ageâ€related EBVâ€associated effusionâ€based lymphoma successfully treated with rituximab and thoracentesis. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03971.	0.5	1
16	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021, 39, 7530-7530.	1.6	1
17	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	1.6	0
18	Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 645-652.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Advances in Radiation Oncology</i> , 2021, 6, 100714.	1.2	6
20	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 67-72.	2.7	1
21	Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 833-838.	1.7	0
22	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	1.4	1
23	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. <i>Blood</i> , 2021, 138, 4020-4020.	1.4	0
24	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	1.4	2
25	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	1.4	0
26	Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 1037-1043.	1.7	4
27	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
28	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. <i>Cancer Genetics</i> , 2020, 240, 40-44.	0.4	8
29	Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4490.	1.6	40
30	A Virtual Screening Platform Identifies Chloroethylglucosylated A as a Potential Ribosomal Inhibitor. <i>Biomolecules</i> , 2020, 10, 1407.	4.0	1
31	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e694-e711.	0.4	13
32	Follicular lymphoma associated paraneoplastic myositis. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2003-2006.	0.5	0
33	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. <i>Blood</i> , 2020, 136, 44-45.	1.4	8
34	Cost Analysis of R-CHOP versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. <i>Clinical Hematology International</i> , 2020, 2, 117.	1.7	2
35	CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 4-5.	1.4	0
36	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	1.4	0

#	ARTICLE	IF	CITATIONS
37	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
38	Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. <i>Cancer Research</i> , 2019, 79, 1535-1548.	0.9	22
39	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , 2019, 94, E245-E247.	4.1	1
40	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.4	4
41	Introduction of novel agents in the treatment of primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 306-313.	1.2	63
42	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
43	Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. <i>Blood</i> , 2019, 134, 2809-2809.	1.4	4
44	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
45	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019, 134, 5327-5327.	1.4	4
46	Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. <i>Blood</i> , 2019, 134, 1544-1544.	1.4	2
47	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	1.4	1
48	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. <i>Blood</i> , 2019, 134, 5610-5610.	1.4	0
49	Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2727-2730.	1.3	2
50	Immune checkpoint inhibition by anti-CD137 (anti-PDCD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. <i>British Journal of Haematology</i> , 2018, 183, 674-678.	2.5	22
51	Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. <i>Blood</i> , 2018, 132, 2240-2248.	1.4	90
52	Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	19
53	Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. <i>Radiation Oncology</i> , 2018, 13, 167.	2.7	14
54	Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 9-13.	1.7	2

#	ARTICLE	IF	CITATIONS
55	Accelerated bottom-up drug design platform enables the discovery of novel stearyl-CoA desaturase 1 inhibitors for cancer therapy. <i>Oncotarget</i> , 2018, 9, 3-20.	1.8	35
56	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. <i>Oncotarget</i> , 2018, 9, 28155-28164.	1.8	4
57	Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B- Cell Lymphoma with High Risk Features. <i>Blood</i> , 2018, 132, 4790-4790.	1.4	0
58	Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. <i>Blood</i> , 2018, 132, 5384-5384.	1.4	1
59	Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 113-119.	5.0	0
60	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. <i>Human Pathology</i> , 2017, 64, 207-212.	2.0	6
61	Hairy Cell Lymphoma: A Potentially Under-Recognized Entity. <i>Rare Tumors</i> , 2017, 9, 1-3.	0.6	7
62	Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma. <i>Blood</i> , 2016, 128, 4170-4170.	1.4	6
63	Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. <i>Oncotarget</i> , 2016, 7, 32156-32171.	1.8	14
64	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma. <i>Rare Tumors</i> , 2015, 7, 160-162.	0.6	3
65	Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Rare Tumors</i> , 2015, 7, 164-166.	0.6	34
66	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	1.4	92
67	A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides. <i>JAAD Case Reports</i> , 2015, 1, 46-48.	0.8	1
68	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 578-585.	0.4	27
69	Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. <i>Cancer Research</i> , 2014, 74, 4796-4810.	0.9	155
70	Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. <i>Oncotarget</i> , 2014, 5, 5320-5334.	1.8	18
71	An integrated approach to the discovery of potent agelastatin A analogues for brain tumors: chemical synthesis and biological, physicochemical and CNS pharmacokinetic analyses. <i>MedChemComm</i> , 2013, 4, 1093.	3.4	19
72	CD47 and Osteopontin Expression in Diffuse Large B-cell Lymphoma With Nodal and Intravascular Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 597-601.	0.4	11

#	ARTICLE	IF	CITATIONS
73	Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models. PLoS ONE, 2013, 8, e71754.	2.5	77
74	Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers. Blood, 2013, 122, 5140-5140.	1.4	0
75	Pharmacokinetics of Agelastatin A in the central nervous system. MedChemComm, 2012, 3, 233-237.	3.4	15
76	Pharmacokinetics of bendamustine in the central nervous system: chemoinformatic screening followed by validation in a murine model. MedChemComm, 2012, 3, 1526.	3.4	8
77	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. International Journal of Clinical and Experimental Pathology, 2012, 5, 72-6.	0.5	9
78	Molecular analysis of intravascular large B cell lymphoma with neoangiogenesis. British Journal of Haematology, 2011, 152, 234-236.	2.5	10
79	Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2010, 5, e10696.	2.5	146
80	Selective central nervous system tropism of primary central nervous system lymphoma. International Journal of Clinical and Experimental Pathology, 2010, 3, 763-7.	0.5	13
81	Differential gene expression of central nervous system lymphoma. Blood, 2009, 113, 267-268.	1.4	7
82	Pathway analysis of primary central nervous system lymphoma. Blood, 2008, 111, 3200-3210.	1.4	156
83	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	1.4	31
84	Platelet Count Is a Sensitive Predictor of Bone Marrow Reserve and Autologous Peripheral Blood Progenitor Cell Mobilization.. Blood, 2005, 106, 5280-5280.	1.4	0
85	Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 47-54.	2.7	2